Analysts Issue Forecasts for Exagen FY2026 Earnings

Exagen Inc. (NASDAQ:XGN) – Investment analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Exagen in a report released on Wednesday, June 11th. Cantor Fitzgerald analyst R. Osborn expects that the company will post earnings per share of ($0.31) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $7.00 price objective on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.88) per share.

Exagen (NASDAQ:XGN) last announced its earnings results on Monday, May 12th. The company reported ($0.20) EPS for the quarter, hitting the consensus estimate of ($0.20). Exagen had a negative net margin of 30.36% and a negative return on equity of 92.58%. The company had revenue of $15.50 million during the quarter, compared to analysts’ expectations of $14.55 million. During the same period last year, the company posted ($0.19) earnings per share.

A number of other analysts have also issued reports on XGN. William Blair reissued an “outperform” rating on shares of Exagen in a research report on Wednesday, March 12th. UBS Group reissued an “overweight” rating on shares of Exagen in a research report on Thursday, May 15th. BTIG Research reissued a “buy” rating on shares of Exagen in a research report on Wednesday, May 7th. Finally, Canaccord Genuity Group increased their price target on shares of Exagen from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Tuesday, May 13th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $7.50.

Exagen Stock Performance

Shares of XGN opened at $7.12 on Friday. Exagen has a one year low of $1.71 and a one year high of $7.56. The company has a 50-day moving average of $6.00 and a two-hundred day moving average of $4.73. The stock has a market cap of $151.66 million, a price-to-earnings ratio of -7.57 and a beta of 1.60. The company has a debt-to-equity ratio of 1.54, a current ratio of 4.05 and a quick ratio of 4.05.

Hedge Funds Weigh In On Exagen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Northern Trust Corp raised its position in Exagen by 16.7% during the fourth quarter. Northern Trust Corp now owns 18,375 shares of the company’s stock valued at $75,000 after acquiring an additional 2,630 shares in the last quarter. Acadian Asset Management LLC bought a new position in Exagen during the first quarter valued at approximately $25,000. Palumbo Wealth Management LLC raised its position in Exagen by 13.5% during the fourth quarter. Palumbo Wealth Management LLC now owns 86,704 shares of the company’s stock valued at $355,000 after acquiring an additional 10,340 shares in the last quarter. Geode Capital Management LLC raised its position in Exagen by 11.9% during the fourth quarter. Geode Capital Management LLC now owns 98,057 shares of the company’s stock valued at $402,000 after acquiring an additional 10,442 shares in the last quarter. Finally, Corient Private Wealth LLC bought a new position in Exagen during the fourth quarter valued at approximately $45,000. Institutional investors own 75.25% of the company’s stock.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).